Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 24, 2020.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
As of February of this year, 121 unique therapies are involved in clinical trials for Alzheimer disease, with putative disease-modifying agents targeting disease onset or progression accounting for the largest number.
The director of the Center for Neurological Restoration at Cleveland Clinic discussed the importance of raising awareness of Parkinson disease on World Brain Day, highlighting the magnitude of the disease.
Crystal Proud, MD, a RESPOND study steering committee member and pediatric neuromuscular neurologist at Children’s Hospital of The King’s Daughters, discussed the goals of the phase 4 trial of Zolgensma in SMA.
Two experts in the field of optic neuritis management, Robert Sergott, MD, and Rod Foroozan, MD, provide a take-home message for community physicians who treat and manage patients with optic neuritis, multiple sclerosis, and disease subtypes.
The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic spoke to the development of the sphingosine-1-phosphate modulator class in MS treatment.